SEVELAMER CARBONATE

Clinical safety rating: safe

Animal studies have demonstrated safety

How it works

Sevelamer carbonate is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and serum phosphate levels. It also binds bile acids and may reduce LDL cholesterol.

What the body does with it

Metabolism	Sevelamer carbonate is not absorbed systemically; thus, it is not metabolized and is excreted unchanged in the feces.
Excretion	Sevelamer carbonate is not absorbed systemically; it acts locally in the gastrointestinal tract. Excretion is entirely fecal, with no renal or biliary elimination. The polymer is excreted unchanged in the feces.
Half-life	Not applicable. Sevelamer carbonate is not systemically absorbed and thus has no measurable plasma half-life. Its pharmacological effect correlates with gastrointestinal transit time, which is typically 24-48 hours.
Protein binding	0%. Sevelamer carbonate is a non-absorbed polymer and does not bind to plasma proteins.
Volume of Distribution	Not applicable. As a non-absorbed drug, volume of distribution is effectively 0 L/kg. It remains within the gastrointestinal lumen.
Bioavailability	Oral: 0% systemically. Sevelamer carbonate is not absorbed; bioavailability refers to local (non-systemic) action only.
Onset of Action	Oral: Onset of serum phosphorus reduction occurs within 1-2 weeks of initiating therapy. Maximal effect is typically seen after 4-8 weeks of consistent dosing.
Duration of Action	Oral: Duration of action is dependent on dosing schedule; due to lack of systemic absorption, the effect is confined to the gastrointestinal tract. The phosphate-binding effect persists for 4-6 hours after a single dose, necessitating administration with meals three times daily.

Classification & Brands

Dosing & administration

Adults: 800 to 1600 mg orally three times daily with meals, titrated according to serum phosphorus targets.

Dosage form	FOR SUSPENSION
Renal impairment	No adjustment required for chronic kidney disease (CKD) or end-stage renal disease (ESRD) as drug is minimally absorbed and excreted renally.
Liver impairment	No dose adjustment necessary in hepatic impairment; drug is not hepatically metabolized.
Pediatric use	Children ≥6 years: Starting dose 800 to 1600 mg/day in divided doses with meals, based on body weight and serum phosphorus level; adjust by 400-800 mg increments every 2-4 weeks to target phosphorus within normal range.
Geriatric use	No specific dose adjustment; initiate at lower end of dosing range and monitor serum phosphorus and electrolytes due to potential for GI side effects and electrolyte disturbances.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Can decrease the absorption of many other drugs administer other drugs 1 hour before or 3 hours after Can cause GI side effects and hypocalcemia.

Breastfeeding	Sevelamer carbonate is not absorbed systemically, so excretion into breast milk is negligible. No M/P ratio available. Considered safe during breastfeeding.
Teratogenic Risk	Sevelamer carbonate is not absorbed systemically, thus unlikely to pose direct teratogenic risk. No human or animal studies have demonstrated fetal harm. However, potential for maternal vitamin deficiency (e.g., vitamin D, folic acid) due to binding may indirectly affect fetal development. Use in pregnancy only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

No FDA boxed warning.

Side Effect Profile

Common Effects	Nausea
Serious Effects

Absolute Contraindications

["Bowel obstruction","Hypersensitivity to sevelamer or any component"]

Clinical Precautions

Precautions

["Bowel obstruction, bleeding, perforation: Cases reported; monitor for constipation and gastrointestinal symptoms.","Dysphagia and esophageal disorders: Use with caution in patients with swallowing disorders or severe gastrointestinal motility disorders.","Reduced absorption of fat-soluble vitamins and folic acid: Monitor levels and supplement if needed.","Hyperchloremic metabolic acidosis: May occur due to chloride-containing formulation (sevelamer hydrochloride), but sevelamer carbonate may reduce risk."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…